Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Return on Sales (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Return on Sales data on record, last reported at 3645.48% in Q3 2025.

  • For Q3 2025, Return on Sales fell 363993.0% year-over-year to 3645.48%; the TTM value through Sep 2025 reached 72.95%, up 7416.0%, while the annual FY2024 figure was 4.04%, 315.0% down from the prior year.
  • Return on Sales reached 3645.48% in Q3 2025 per CAPR's latest filing, down from 61.5% in the prior quarter.
  • Across five years, Return on Sales topped out at 6.15% in Q4 2024 and bottomed at 3645.48% in Q3 2025.
  • Average Return on Sales over 5 years is 322.21%, with a median of 8.01% recorded in 2022.
  • Peak YoY movement for Return on Sales: surged 17012bps in 2021, then tumbled -363993bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 85.26% in 2021, then surged by 91bps to 8.01% in 2022, then surged by 99bps to 0.07% in 2023, then skyrocketed by 9067bps to 6.15% in 2024, then tumbled by -59372bps to 3645.48% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 3645.48% in Q3 2025, 61.5% in Q2 2025, and 1942.6% in Q1 2025.